Oncodesign SA (ALONC):企業のM&A・提携動向(医療分野)

【英語タイトル】Oncodesign SA (ALONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(GDPH132689D)・商品コード:GDPH132689D
・発行会社(調査会社):GlobalData
・発行日:2016年12月13日
・ページ数:33
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥27,750見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥55,500見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥83,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Oncodesign SA (Oncodesign) is a biotechnology company that offers drug discovery and pharmacological evaluation services for cancer. The company offers a wide range of products and services for the validation, assessment, targeting and diagnostic linking of anti-cancer therapies based on its technological platforms. Its business activities include preclinical evaluation services comprising a range of products and services for the assessment and validation of anti-cancer therapies and biomarker development and monitoring; and drug discovery, among others. Oncodesign’s technological platforms includes PREDICT, a conventional in vitro and in vivo pharmacology platform; Pharm’Image, a multi-modal and non-invasive pharmaco-imaging platform; Chi-Mice that concentrates on developing in vivo chimeric experimental models; and Nanocyclix, for the synthesis and optimization of novel compounds used for diagnostic and therapeutic purpose. The company operates in Europe, and American countries. Oncodesign is headquartered in Dijon, France.

Oncodesign SA (ALONC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncodesign SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Oncodesign SA, Medical Devices Deals, 2010 to YTD 2016 9
Oncodesign SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Oncodesign SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 11
Partnerships 13
Ipsen Partners with Oncodesign 13
Oncodesign Enters into Agreement with Bristol-Myers Squibb 14
Oncodesign Enters Into Research Agreement With Sanofi 15
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson’s Disease 16
Sanofi Enters Into Research Agreement With Oncodesign 18
Oncodesign Enters Into Research Agreement With Ipsen For LRRK2 Inhibitors 19
Taconic Farms Enters Into Co-Development Agreement With Oncodesign 21
Oncodesign Enters Into Co-Marketing Agreement For Colorectal Cancer Models 23
Licensing Agreements 24
UCB Exercises Option for Licensing Agreement with Oncodesign 24
Oncodesign Enters Into Licensing Agreement With Janssen Pharmaceutica 26
Equity Offering 27
Oncodesign Raises Funds through Private Placement of Shares 27
Oncodesign Raises USD17.8 Million in IPO 28
Oncodesign SA – Key Competitors 30
Key Employees 31
Locations And Subsidiaries 32
Head Office 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Oncodesign SA, Pharmaceuticals & Healthcare, Key Facts, 2015 1
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncodesign SA, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncodesign SA, Deals By Therapy Area, 2010 to YTD 2016 8
Oncodesign SA, Medical Devices Deals, 2010 to YTD 2016 9
Oncodesign SA, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Oncodesign Acquires Francois Hyafil Research Centre from GlaxoSmithKline 11
Ipsen Partners with Oncodesign 13
Oncodesign Enters into Agreement with Bristol-Myers Squibb 14
Oncodesign Enters Into Research Agreement With Sanofi 15
Oncodesign And Laboratory For Neurobiology and Gene Therapy Enter Into Research Agreement With Ipsen For Parkinson's Disease 16
Sanofi Enters Into Research Agreement With Oncodesign 18
Oncodesign Enters Into Research Agreement With Ipsen For LRRK2 Inhibitors 19
Taconic Farms Enters Into Co-Development Agreement With Oncodesign 21
Oncodesign Enters Into Co-Marketing Agreement For Colorectal Cancer Models 23
UCB Exercises Option for Licensing Agreement with Oncodesign 24
Oncodesign Enters Into Licensing Agreement With Janssen Pharmaceutica 26
Oncodesign Raises Funds through Private Placement of Shares 27
Oncodesign Raises USD17.8 Million in IPO 28
Oncodesign SA, Key Competitors 30
Oncodesign SA, Key Employees 31

List of Figures
Oncodesign SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Oncodesign SA, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Oncodesign SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Oncodesign SA, Medical Devices Deals, 2010 to YTD 2016 9

★調査レポート[Oncodesign SA (ALONC):企業のM&A・提携動向(医療分野)] (コード:GDPH132689D)販売に関する免責事項を必ずご確認ください。
★調査レポート[Oncodesign SA (ALONC):企業のM&A・提携動向(医療分野)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆